Cheetah Medical Announces European Launch of a New NICOM(R) System for Advanced Noninvasive Hemodynamic Monitoring and Fluid Management

Cheetah's Noninvasive Hemodynamic Monitoring System now Available With Integrated Pulse Oxymetry and Oxygen Delivery Functionality to Expedite Fluid Optimization, Goal-Directed Therapy and Comprehensive Hemodynamic Management

TEL AVIV, Israel, October 15, 2010 - Cheetah Medical today announced the European launch of its new
NICOM(R) System which offers an integrated Pulse Oximetry functionality
(OxiMax(R) Covidien plc). In addition to core hemodynamic parameters
including Cardiac Output (CO), Stroke Volume (SV), Noninvasive Blood Pressure
(NIBP), Total Peripheral Resistance (TPR) and Stroke Volume Variation (SVV),
the new system provides a new important parameter, Oxygen Delivery Index
(DO2I).

DO2I is a key indicator of oxygen delivery to the organs and
tissues which is increasingly used to guide crucial resuscitation decisions
in septic, surgical and other critically ill patients. It is a product of the
amount of blood supplied to the tissues, also known as Cardiac Output and the
blood oxygen content. In addition, the NICOM 3.0 now offers a user friendly,
intuitive touch-screen and real-time event-marking to enable rapid onset of
monitoring and has interfacing capabilities with hospital monitoring and
electronic systems.

Daniel Burkhoff, M.D., Ph.D., Medical Director of Cheetah
Medical and a leading clinical researcher in the field of heart failure said:
"Accurate continuous hemodynamic monitoring to guide decisions on fluid
management and drug titration is quickly becoming a vital component of
treatment of the most common life-threatening conditions, including sepsis,
heart failure and high-risk surgery. The addition of Oxygen Delivery Index
provides clinicians with yet another previously validated important parameter
that can be used to implement up-to-date goal directed resuscitation
approaches."

Yoav Avidor MD, CEO of Cheetah Medical added: "With the
increase in prevalence of sepsis, heart failure and major surgical procedures
and the awareness for the pivotal role of fluid resuscitation in outcomes and
costs, hospitals are looking for accurate and practical technologies that
help tailor fluids and hemodynamic drugs to patient's vital signs. With added
Pulse Oximetry and DO2I functionality Cheetah's NICOM now empowers physicians
and nurses with a comprehensive suite of information for fluid management in
critically ill patients, all in 100% noninvasive fashion. Our goal is to help
providers to keep in line with contemporary, cutting edge care without the
need for legacy invasive instrumentation and help clear the way for
significant expansion of critical treatments to more patients and sites of
care."

About Cheetah Medical

Cheetah Medical's NICOM(R) Noninvasive Cardiac Output and
Hemodynamic Monitoring System uses the company's proprietary BIOREACTANCE(R)
Technology to deliver continuous, accurate, noninvasive cardiac output (CO)
and other vital hemodynamic monitoring parameters. The system is US FDA
cleared and CE Marked, and since its commercial launch in 2008 has been
adopted by a growing number of clinicians worldwide. Cheetah Medical
headquarters is located in Tel-Aviv, Israel and its United States
headquarters is located in Portland, Oregon. For more information, visit our
website at www.cheetah-medical.com.

    For More Information Contact:

    Yoav Avidor, MD
    Chief Executive Officer
    Cheetah Medical
    yoav@cheetah-medical.com
    Telephone: +972-644-0288

For More Information Contact: Yoav Avidor, MD, Chief Executive Officer, Cheetah Medical, yoav at cheetah-medical.com , Telephone: +972-644-0288.